<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>An announcement from BeOne Medicines Ltd ( (HK:6160) ) is now available. BeOne Medicines Ltd. has filed a shelf registration statement on Form S-3 with the U.S. Securities and Exchange Commission, enabling it to offer securities on a delayed or continuous basis in the U.S. market. The move underscores the Swiss-based, Hong Kong-listed drug developer’s effort to maintain flexible access to U.S. capital markets, potentially supporting future financing activities and strengthening its cross-border capital structure for global investors. The company’s filing will become effective automatically under streamlined rules applicable to large accelerated filers, reflecting its status as a more mature issuer in U.S. markets. BeOne’s latest disclosure, made in parallel with its obligations under Hong Kong listing rules, highlights the firm’s dual-market regulatory compliance and may broaden its funding options as it advances its business strategy. The most recent analyst rating on (HK:6160) stock is a Buy with a HK$290.00 price target. To see the full list of analyst forecasts on BeOne Medicines Ltd stock, see the HK:6160 Stock Forecast page. More about BeOne Medicines Ltd BeOne Medicines Ltd. is a Switzerland-incorporated company whose shares are listed in Hong Kong and it is also registered with the U.S. Securities and Exchange Commission. The company operates in the biopharmaceutical sector, with an international presence that includes principal executive offices in Basel and a U.S. base in Cambridge, Massachusetts. Average Trading Volume: 3,721,116 Technical Sentiment Signal: Buy Current Market Cap: HK$263.1B For a thorough assessment of 6160 stock, go to TipRanks’ Stock Analysis page.</div>

BGNE

06160

IBBQ

BeOne Medicines Ltd has filed a Form S-3 with the U.S. SEC to enable delayed or continuous securities offerings in the U.S. market. This move aims to enhance its access to U.S. capital markets, supporting future financing and strengthening its global investor appeal. The filing reflects BeOne's compliance with both U.S. and Hong Kong regulations, potentially broadening its funding options. The latest analyst rating for BeOne's stock (HK:6160) is a Buy, with a price target of HK$290.00.

BeOne Medicines Files Form S-3 to Expand U.S. Capital Market Access